Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein.
Acylation-stimulating protein (ASP) is a small, basic, human plasma protein that markedly stimulates triglyceride synthesis in human adipocytes and cultured human skin fibroblasts. The present studies examine the response to ASP of cultured skin fibroblasts from normal subjects patients with hyperapobetalipoproteinemia, patients with familial hypercholesterolemia, and patients with hypertriglyceridemia without hyperapobetalipoproteinemia. Triglyceride synthesis induced by ASP did not differ significantly among the normals, the patients with familial hypercholesterolemia, and the patients with hypertriglyceridemia with normal low density lipoprotein (LDL) apolipoprotein B levels; however, on average, it was markedly reduced in the patients with hyperapobetalipoproteinemia. In all groups studied, evidence of specific saturable binding of radioiodinated ASP was present. Binding, however, was significantly reduced in the groups with hyperapobetalipoproteinemia whereas the other three groups were indistinguishable. By contrast, LDL-specific binding was reduced only in the patients with familial hypercholesterolemia. There was a significant direct relation between the degree of ASP binding and the triglyceride synthesis inducible by ASP. In addition, with the exception of the patients with familial hypercholesterolemia, there was an inverse relation between both ASP-specific binding and ASP-induced triglyceride synthesis in fibroblasts to LDL levels in plasma whereas no relation was evident to plasma high density lipoprotein and very low density lipoprotein.
Cianflone
K M
KM
McGill Unit for the Prevention of Cardiovascular Disease, Royal Victoria Hospital, Montreal, Quebec, Canada.
Maslowska
M H
MH
Sniderman
A D
AD
D000293:Adolescent; D000328:Adult; D000368:Aged; D001055:Apolipoproteins B / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism / Q000494:pharmacology*; D002478:Cells, Cultured; D002648:Child; D015926:Complement C3a / Q000031:analogs & derivatives*; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000096:biosynthesis
D001055:Apolipoproteins B; D001798:Blood Proteins; D005227:Fatty Acids; D008077:Lipoproteins, LDL; D014280:Triglycerides; C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a